WebMar 10, 2024 · AcelRx expanded late-stage pipeline with Niyad ™ (nafamostat), which has received Breakthrough Designation status from the FDA and an ICD-10 procedural code from CMS Q4 2024 DSUVIA unit sales growth of 142% compared to Q3 2024 AcelRx had $51.6 million of cash and short-term investments as of December 31, 2024 WebNov 15, 2024 · AcelRx to expand its pipeline with Niyad™, Lowell's investigational product that has received Breakthrough Designation status from the FDA Lowell provides AcelRx …
Home AcelRx Pharmaceuticals, Inc.
WebFeb 5, 2024 · According to the 4 industry analysts covering AcelRx Pharmaceuticals, the consensus is that breakeven is near. They expect the company to post a final loss in 2024, before turning a profit of... WebProfile. AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. trishawn kipp
Interactive map of pipelines in the United States
WebAug 11, 2024 · AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in … WebApr 4, 2024 · And we look and remain focused on driving long-term shareholder value with advancing this high-value, late-stage pipeline. I look forward to answering any additional questions you might have ... WebAcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. trishaw bicycle for sale